CAPS

SEC Filing Summary: OrthoLogic Corp. (Capstone Therapeutics)

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2008. The registrant, OrthoLogic Corp., began operating under the trade name Capstone Therapeutics on October 1, 2008. The company is a biotechnology firm in the development stage with no revenue-generating operations. Its business focuses on two peptide product platforms: AZX100 (for dermal scarring, pulmonary disease, and intimal hyperplasia) and Chrysalin (for vascular applications and tissue repair). The company sold its former bone device business in 2003 and has incurred cumulative net losses of approximately $113 million since becoming a development-stage entity.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by approximately $1.1 million (11%) from 2007 to 2008. This was driven primarily by increased R&D costs for AZX100 Phase 1 clinical trials and reduced interest income due to lower interest rates and reduced investment balances.
• Expense Management: General and Administrative (G&A) expenses decreased by $747,000 (20%) due to cost containment efforts.
• Investment Portfolio: Long-term investments decreased significantly from $21.5 million in 2007 to $2.2 million in 2008, as the company reclassified or matured assets, shifting liquidity to short-term investments and cash.
• Stock Repurchases: The company repurchased 1,131,622 shares of common stock during 2008 at a total cost of $1.04 million under a board-approved program.
• Tax Benefit: A $363,000 income tax benefit was recorded in 2008 due to the reversal of a FIN 48 reserve as the statute of limitations expired for certain tax years.

Guidance, Outlook, and Risks

• Development Outlook: The company plans to initiate Phase 2 human clinical efficacy studies for AZX100 in dermal scarring in the first quarter of 2009. For Chrysalin, the company has shifted strategy to pursue development partnering or licensing opportunities rather than independent clinical trials, focusing on pre-clinical vascular studies.
• Liquidity: Management anticipates that cash and short-term investments (totaling approximately $45.8 million) are sufficient to meet projected requirements for the next year. However, future funding may be required if clinical trials expand or if partnering opportunities are not secured.
• Key Risks:
  • NASDAQ Delisting: The company received notice in August 2008 that its stock price fell below the $1.00 minimum bid price requirement for over 30 days. Failure to regain compliance could result in delisting.
  • Development Failure: As a pre-revenue biotech, the company faces significant risk that product candidates will fail clinical trials or not receive FDA approval.
  • Capital Needs: There is no assurance that additional capital will be available on acceptable terms if current cash reserves are depleted.

Investor Verification Checklist

• Cash Runway: Verify if the $45.8 million in liquid assets is sufficient to fund the planned Phase 2 AZX100 trials and ongoing operations for the projected 12-month period without additional financing.
• NASDAQ Compliance: Monitor the company's status regarding the minimum bid price requirement and any plans to cure the deficiency to avoid delisting.
• Chrysalin Strategy: Assess the progress of the strategic shift toward licensing/partnering for Chrysalin, as the company is no longer pursuing independent clinical trials for this platform.
• Stock Repurchase Impact: Review the remaining authorization under the stock repurchase program and its impact on share count and liquidity.
• Patent Expirations: Note that certain Chrysalin patents have expired or are expiring (e.g., US patent expires in 2011), which may impact the value of the asset for potential partners.